Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the european institute of oncology group

This publication has 22 references indexed in Scilit:

• Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides
  Current Medicinal Chemistry, 2000
• Receptor-mediated Radionuclide Therapy with ⁹⁰Y-DOTA-D-Phe¹-Tyr³-Octreotide: Preliminary Report in Cancer Patients
  Cancer Biotherapy & Radiopharmaceuticals, 1999
• Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy
  Chemistry – A European Journal, 1999
• Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels
  Metabolism, 1996
• High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor‐host interaction?
  International Journal of Cancer, 1994
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
  European Journal of Nuclear Medicine and Molecular Imaging, 1993
• Somatostatin-Receptor Imaging in the Localization of Endocrine Tumors
  New England Journal of Medicine, 1990
• The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid and study of its yttrium(III) complex
  Journal of the American Chemical Society, 1988
• Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
  Science, 1973
• Stimulatory and Inhibitory Effects of Purified Hypothalamic Extracts on Growth Hormone Release from Rat Pituitaryin Vitro¹
  Endocrinology, 1968